Mental Health

A new partnership puts therapy on prison tablets, promising a revolution in rehabilitation. But does this tech-forward approach truly serve reform?

A new study reveals why Sickle Cell Disease patients suffer from frequent crises and rely on pain pills, even with awareness of multi-million dollar cures.

As concerns over screen time's impact on children grow, a movement back to tactile, imagination-driven play is gaining momentum at this year's NY Toy Fair.

New grants from the American Psychological Foundation fund direct interventions for trans youth and trauma-affected families, moving psychology from theory to action.

A new report reveals a grim reality: the typical American worker has under $1,000 for retirement. Is the system, not the saver, fundamentally broken?

A new partnership aims to revolutionize sleep and allergy treatment with FDA-cleared, AI-personalized wearables, moving beyond tracking to active intervention.

The 2026 Special Olympics USA Games in Minnesota needs 10,000 volunteers. Discover the roles available and why many say the experience is life-changing.

The Rainwater Foundation awards $600,000 to pioneering scientists, accelerating breakthroughs in treating devastating neurodegenerative tauopathies.

New polls show Bad Bunny's Super Bowl act is highly anticipated, but his real impact is in forcing conversations on gentrification and violence in Puerto Rico.

A new report reveals a looming crisis: rising healthcare costs will consume more than 100% of Social Security benefits for future generations of retirees.

VectorY Therapeutics adds seasoned biotech architect Kevin Pojasek to its board, signaling a strategic push to accelerate its novel therapies for ALS and Alzheimer's.

Two industry titans are tackling a major pain point for millions, aiming to make eye makeup safe and comfortable for all contact lens wearers.

Refurbished tech is mainstream. Back Market's $3.5B in sales proves a major shift, fueled by AI, cloud services, and a new generation of savvy consumers.

Amid financial scrutiny and following a major trial failure, Vistagen's upcoming Q3 update is a critical test for its novel pherine pipeline.

MetaVia's drug vanoglipel gets a major boost from AI modeling, validating its potential to treat complex metabolic diseases like MASH and Type 2 Diabetes.

An expanded partnership aims to deliver a once-daily oral tablet for hypoparathyroidism, potentially revolutionizing treatment for thousands of patients.

Affinia Therapeutics gets the green light for a human trial of AFTX-201, a one-time therapy for a devastating genetic heart disease, BAG3 DCM.

With crucial data on its novel oral inflammation inhibitor looming, NodThera brings in seasoned leader Geoff McDonough to navigate the path to Phase 3.

New 4-year real-world data shows Zevra's drug stabilizes the rare, fatal 'Childhood Alzheimer's' disease, marking a milestone for patients and families.

During Super Bowl week, NAMI, Dan Marino, and NFL families are launching a major initiative to destigmatize mental health in sports and beyond.